MB "ANG Pharma" Finance - revenue, profit
EBITDA margin (%)
Register and
explore Okredo dataEBIT margin (%)
Register and
explore Okredo dataFinancial statetment report
Price: €9.90
Premium users: 1.00 credit
Premium users: 1.00 credit
Indicator |
---|
Turnover (€) |
Sales per employee (€) |
Profit before tax (€) |
Net Profit (€) |
Profit per employee (€) |
Working capital requirement |
Debt-to-equity ratio |
Total profitability (%) |
Net profitability (%) |
Equity (€) |
Amounts Payable And Liabilities (€) |
Non-current Assets (€) |
CurrentAssets (€) |
EBITDA margin (%) |
EBITDA (€) |
EBIT margin (%) |
EBIT (€) |
2021 |
---|
0 |
- |
0 |
0 |
- |
- |
- |
- |
- |
0 |
0 |
0 |
0 |
2022 |
---|
1,549 |
- |
-5,908 |
-5,908 |
- |
7.81 |
-3.30 |
63.65 |
-381.41 |
-5,908 |
19,501 |
0 |
13,593 |
2023 |
---|
38,045 |
- |
7,853 |
7,693 |
- |
0.60 |
14.51 |
63.90 |
20.22 |
1,785 |
25,906 |
0 |
27,691 |
Register and
explore Okredo data2023 |
---|
38,045 |
- |
7,853 |
7,693 |
- |
0.60 |
14.51 |
63.90 |
20.22 |
1,785 |
25,906 |
0 |
27,691 |
Register and
explore Okredo data2023
Turnover (€)
38,045 €2,356 % *
Sales per employee (€)
-Profit before tax (€)
7,853 €233 % *
Net Profit (€)
7,693 €230 % *
Profit per employee (€)
-Working capital requirement
0.60 -92.32 % *
Debt-to-equity ratio
14.51 539.70 % *
Total profitability (%)
63.90 %0.39 % *
Net profitability (%)
20.22 %105.30 % *
Equity (€)
1,785 €130 % *
Amounts Payable And Liabilities (€)
25,906 €33 % *
Non-current Assets (€)
0 €- *
CurrentAssets (€)
27,691 €104 % *